drugset / Trial / NCT07002320
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Phase 1/2
Recruiting
78 enrolled
Institute of Cancer Research, United Kingdom
Belfast Health and Social Care Trust · collabCambridge University Hospitals NHS Foundation Trust · collabInstitute of Oncology Research (IOR) · collabJanssen Pharmaceutica N.V., Belgium · collabOncology Institute of Southern Switzerland · collabProstate Cancer UK · collabRoyal Marsden NHS Foundation Trust · collabSyntrix Biosystems, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2025-04-28
- Primary completion
- 2029-10
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SX-682 | Small molecule | 100 mg | — |
| Background | Apalutamide | Small molecule | 60 mg | — |